We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Daily Soy Isoflavone Supplement Presents No Risks For Healthy Postmenopausal Women

February 1, 2011: 08:36 AM EST

A randomized two-year clinical trial involving 403 healthy postmenopausal women has found that a daily 80-120 mg supplement of soy hypocotyl isoflavones does not present a health risk, and may actually protect against cancer. The trial was designed to test the impact of soy isoflavone supplementation on osteoporosis, but researchers were also trying to determine if long-term supplementation led to adverse health outcomes. Only two women in the soy supplement groups  experienced serious health problems: one case of breast cancer and one case of endometrial cancer. This “was less than the expected population rate for these cancers,” the researchers said. The supplement used in the study was the patented soy germ isoflavone product SoyLife from Frutarom.

Francene M Steinberg, et al., "Clinical outcomes of a 2-year soy isoflavone supplementation in menopausal women", American Journal of Clinical Nutrition, February 01, 2011, © American Society for Nutrition
Food Safety
North America
United States of America
Middle East- Africa
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.